ProQR Therapeutics N.V.
NASDAQ:PRQR
1.69 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 18.905 | 6.514 | 4.037 | 1.354 | 0 | 1.933 | 4.941 | -1.529 | 2.282 | 9.407 | 0.313 | 0 |
| Cost of Revenue
| 0 | 0.134 | 2.476 | 0 | 2.194 | 116.823 | 0.984 | 1.001 | 1.282 | 0.483 | 0 | 0 |
| Gross Profit
| 18.905 | 6.38 | 1.561 | 1.354 | -2.194 | -114.89 | 3.957 | -2.53 | 1 | 8.924 | 0.313 | 0 |
| Gross Profit Ratio
| 1 | 0.98 | 0.387 | 1 | 0 | -59.436 | 0.801 | 1.655 | 0.438 | 0.949 | 1 | 0 |
| Reseach & Development Expenses
| 36.356 | 25.148 | 50.867 | 42.22 | 38.135 | 46.491 | 29.514 | 31.153 | 31.923 | 23.401 | 10.267 | 2.569 |
| General & Administrative Expenses
| 13.661 | 16.236 | 18.651 | 17.368 | 13.685 | 12.887 | 12.54 | 10.84 | 9.478 | 6.837 | 6.507 | 0.786 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.661 | 16.236 | 18.651 | 17.368 | 13.685 | 12.887 | 12.54 | 10.84 | 9.478 | 6.837 | 6.507 | 0.786 |
| Other Expenses
| -0.64 | -3.011 | -0.765 | -1.043 | 9.368 | 1.933 | 5.761 | 1.495 | 1.828 | 3.235 | 0.313 | 0 |
| Operating Expenses
| 49.377 | 38.373 | 68.753 | 58.545 | 51.82 | 59.378 | 42.054 | 41.993 | 41.401 | 30.238 | 16.774 | 3.239 |
| Operating Income
| -30.472 | -31.859 | -64.716 | -57.191 | -42.368 | -57.445 | -36.293 | -40.498 | -39.573 | -27.003 | -16.461 | -3.239 |
| Operating Income Ratio
| -1.612 | -4.891 | -16.031 | -42.239 | 0 | -29.718 | -7.345 | 26.487 | -17.341 | -2.871 | -52.591 | 0 |
| Total Other Income Expenses Net
| 2.512 | 4.046 | 1.051 | -3.472 | -4.122 | 117.654 | -0.792 | 0.85 | 0.47 | 6.171 | 4.334 | -0.014 |
| Income Before Tax
| -27.96 | -27.813 | -64.795 | -61.563 | -46.49 | -56.614 | -37.085 | -43.673 | -39.103 | -20.832 | -12.127 | -3.253 |
| Income Before Tax Ratio
| -1.479 | -4.27 | -16.05 | -45.468 | 0 | -29.288 | -7.506 | 28.563 | -17.135 | -2.215 | -38.744 | 0 |
| Income Tax Expense
| -0.197 | -0.078 | 0.096 | 0.117 | 0.124 | 0.132 | 0.001 | 0.002 | -0.47 | -6.171 | -4.334 | 0.024 |
| Net Income
| -27.763 | -28.119 | -64.891 | -61.68 | -46.614 | -56.746 | -36.894 | -43.637 | -39.103 | -20.832 | -12.127 | -3.253 |
| Net Income Ratio
| -1.469 | -4.317 | -16.074 | -45.554 | 0 | -29.356 | -7.467 | 28.54 | -17.135 | -2.215 | -38.744 | 0 |
| EPS
| -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted
| -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EBITDA
| -24.122 | -24.097 | -56.46 | -54.948 | -136.556 | -174.268 | -35.291 | 0 | -120.547 | -84.244 | -49.696 | -3.191 |
| EBITDA Ratio
| -1.276 | -3.699 | -14.71 | -40.898 | 0 | -29.656 | -8.31 | 26.768 | -17.597 | -3.163 | -53.188 | 0 |